RPL29 Antibody

What is RPL29 and why is it studied using antibodies?

RPL29 is a component of the large (60S) ribosomal subunit abundantly expressed in all cell types. It plays a regulatory role in translation efficiency and is essential for protein synthesis . Beyond its canonical function in ribosomes, RPL29 has been identified as a major substrate for the lysine methyltransferase Set7/9 and as a regulator of angiogenesis . Antibodies against RPL29 are essential tools to study its expression patterns, post-translational modifications, and functions in various cellular processes and disease states.

What applications are RPL29 antibodies validated for?

RPL29 antibodies have been validated for multiple applications including Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)/Immunocytochemistry (ICC), Flow Cytometry (FC), and ELISA . Most commercially available antibodies demonstrate reactivity with human, mouse, and rat samples, making them versatile for comparative studies across species . For Western blotting, dilution ratios typically range from 1:2000 to 1:50000 depending on the specific antibody . For immunofluorescence applications, recommended dilutions range from 1:200 to 1:800 .

What is the expected molecular weight of RPL29 in experimental analyses?

Though the calculated molecular weight of RPL29 is approximately 18 kDa (159 amino acids), the observed molecular weight in experimental analyses typically ranges between 20-25 kDa . This discrepancy between calculated and observed molecular weights may be attributed to post-translational modifications or the protein's specific biochemical properties. When conducting Western blot analyses, researchers should expect to detect bands in the 20-25 kDa range when using validated RPL29 antibodies.

Which cell and tissue types are suitable for RPL29 antibody validation?

Several cell lines have been successfully used to validate RPL29 antibodies, including HeLa cells, HepG2 cells, PC-3 cells, U-87 MG cells, C6 cells, NIH/3T3 cells, HEK-293T cells, and HUVEC cells . For tissue samples, mouse pancreas tissue, mouse brain tissue, human breast cancer tissue, and human liver cancer tissue have been successfully used for antibody validation in immunohistochemistry applications . This diverse range of validated samples makes RPL29 antibodies applicable across multiple research contexts.

How can researchers distinguish between different methylation states of RPL29 using antibodies?

RPL29 undergoes methylation at lysine 5 (Rpl29K5) exclusively by Set7/9 methyltransferase . Researchers interested in studying this specific post-translational modification can use specialized antibodies like the dimethyl-RPL29 (Lys-5) (D8T9P) rabbit monoclonal antibody, which has been developed to detect dimethylated RPL29 at lysine 5 . This antibody exhibits strong reactivity with dimethyl peptides, slight cross-reactivity with monomethyl peptides, and no reactivity with trimethyl and unmodified peptides . For experimental validation, researchers should include appropriate controls such as Set7/9 knockout cells or Rpl29 K5R mutants which cannot be methylated at this position.

What considerations are important when studying RPL29 methylation as a biomarker for Set7/9 activity?

RPL29K5 methylation has been identified as a specific cellular biomarker for Set7/9 activity, making it valuable for developing and testing therapeutics that target Set7/9 . When using RPL29 methylation as a biomarker, researchers should consider that:

• RPL29K5 methylation levels positively correlate with SET7/9 levels and negatively correlate with LSD1 levels

• The Set7/9 inhibitor (R)-PFI-2 efficiently reduces Rpl29K5 methylation in cells

• RPL29K5 methylation is ubiquitously detected in cancer cell lines, though its levels show greater variations compared to total RPL29 levels

For accurate assessment, researchers should simultaneously measure total RPL29 levels, RPL29K5 methylation, and the expression levels of SET7/9 and LSD1 to account for all variables that may influence methylation status.

How can RPL29 antibodies be utilized to investigate angiogenesis regulation?

RPL29 has been identified as a regulator of angiogenesis, with loss or deletion of RPL29 in endothelial cells inhibiting vascular sprouting . To investigate this function:

• Use RPL29 antibodies in conjunction with endothelial cell markers in co-immunostaining experiments to assess RPL29 expression in vascular structures

• Compare RPL29 expression between normal and tumor-associated blood vessels using immunohistochemistry

• Combine RNA interference approaches targeting RPL29 with functional angiogenesis assays (such as tube formation assays or aortic ring sprouting assays)

• Analyze RPL29 expression in β3-integrin null endothelial cells, which show significant upregulation of RPL29 at both mRNA and protein levels

Results from these experiments could provide insights into potential anti-angiogenic therapeutic strategies targeting RPL29.

What protocol optimizations are recommended for Western blot detection of RPL29?

For optimal Western blot detection of RPL29:

• Use the appropriate dilution range (1:2000-1:50000 depending on the specific antibody)

• Expect to visualize bands at 20-25 kDa, despite the calculated molecular weight of 18 kDa

• Include both positive controls (cells with known RPL29 expression like HeLa or HepG2) and negative controls (RPL29 knockout cells if available)

• For phosphorylation or methylation-specific antibodies, include appropriate controls such as Set7/9 knockout samples or samples treated with methyltransferase inhibitors

• Use PVDF membranes for better protein retention and signal strength

• For heavily expressed ribosomal proteins like RPL29, use reduced sample loading (5-10 μg total protein) to avoid signal saturation

These optimizations will help ensure specific detection and quantification of RPL29 in Western blot applications.

What are the recommended protocols for immunofluorescence staining of RPL29?

For successful immunofluorescence detection of RPL29:

• Use recommended dilutions between 1:200-1:800 for most RPL29 antibodies

• Validated cell lines include HepG2 cells, which have been confirmed to show positive staining with RPL29 antibodies

• For fixation, use 4% paraformaldehyde for 10-15 minutes at room temperature

• For permeabilization, use 0.1-0.3% Triton X-100 for 5-10 minutes

• Include adequate blocking (3-5% BSA or 5-10% normal serum from the species of the secondary antibody)

• For co-localization studies, consider using markers for nucleoli (where ribosomal proteins are often found) or ribosomes

• For methylated RPL29 detection, nuclear enrichment should be visible when using methylation-specific antibodies

These protocols enable detailed visualization of RPL29 cellular localization and potential changes under different experimental conditions.

How should flow cytometry experiments be designed for RPL29 detection?

For flow cytometry detection of RPL29:

• Use the recommended dilution of 0.25 μg per 10^6 cells in a 100 μl suspension

• RPL29 is an intracellular protein, requiring proper cell fixation and permeabilization protocols

• For fixation, use 2-4% paraformaldehyde for 10-15 minutes

• For permeabilization, use 0.1% saponin or 0.1-0.3% Triton X-100

• Include appropriate isotype controls to establish gating strategies

• For dual staining with cell surface markers, perform surface staining before fixation and permeabilization

• HeLa cells have been validated for positive flow cytometry detection of RPL29

This approach allows for quantitative assessment of RPL29 expression at the single-cell level across different cell populations.

How can RPL29 antibodies be used to investigate cancer biology?

RPL29 expression is up-regulated in human carcinomas and constitutes a candidate marker for abnormal growth when overexpressed . Researchers studying cancer biology can use RPL29 antibodies to:

• Compare RPL29 expression levels between normal and cancerous tissues using immunohistochemistry

• Correlate RPL29 expression with tumor growth rates, invasion, and metastasis

• Investigate whether RPL29 methylation status correlates with cancer progression

• Determine if RPL29 expression can serve as a prognostic biomarker in specific cancer types

• Study the impact of targeting RPL29 on both tumor cells and tumor vasculature, as RPL29 plays roles in both protein synthesis and angiogenesis

Human breast cancer tissue and human liver cancer tissue have been successfully used for immunohistochemical detection of RPL29 , providing starting points for cancer-related investigations.

What approaches are recommended for studying RPL29 in the context of angiogenesis?

To study RPL29's role in angiogenesis:

• Use ex vivo models such as aortic ring sprouting assays comparing wild-type, RPL29-heterozygous, and RPL29-null samples

• Analyze tumor blood vessel density in subcutaneously grown tumors in wild-type versus RPL29-mutant mice

• Employ RNA interference approaches targeting RPL29 to assess effects on VEGF-induced angiogenic responses

• Compare RPL29 expression in β3-null versus wild-type endothelial cells using both antibody-based detection and mRNA analysis

• Investigate potential interactions between RPL29 and known angiogenesis regulators

These approaches can help elucidate RPL29's role in vascular biology and may identify new anti-angiogenic therapeutic targets.

How can researchers investigate the role of RPL29 methylation in protein synthesis and cellular localization?

To study the functional significance of RPL29 methylation:

• Use methylation-specific antibodies to compare the subcellular localization of methylated versus unmethylated RPL29

• Perform ribosome profiling experiments comparing wild-type cells, Set7/9 knockout cells, and cells expressing RPL29 K5R mutants

• Assess global protein synthesis rates using methods like puromycin incorporation in the presence or absence of RPL29 methylation

• Create stable cell lines expressing fluorescently tagged wild-type RPL29 versus K5R mutants to observe real-time localization differences

• Use immunoprecipitation with methylation-specific antibodies followed by mass spectrometry to identify potential interacting partners specific to methylated RPL29

Previous research has shown that RPL29K5 methylation facilitates nuclear enrichment of RPL29 but has no effect on global protein synthesis , suggesting specialized functions for this modification.

What are common issues in RPL29 western blotting and how can they be resolved?

Common challenges in RPL29 Western blotting include:

• Multiple bands or non-specific binding: Increase antibody dilution (1:10000-1:50000) and ensure adequate blocking (5% non-fat milk or 3-5% BSA)

• No signal: Verify sample preparation (ribosomal proteins require specific extraction methods); reduce dilution (1:2000-1:5000) ; ensure transfer efficiency for small proteins by using PVDF membranes and appropriate transfer conditions

• Inconsistent results between experiments: Standardize lysate preparation methods; use housekeeping controls appropriate for ribosomal protein normalization; consider the impact of cell growth conditions on ribosomal protein expression

• Discrepancies between total RPL29 and methylated RPL29 detection: Always run parallel blots with total RPL29 antibodies when using modification-specific antibodies; consider that methylation levels vary across cell types and depend on SET7/9 and LSD1 expression

Including appropriate positive controls (HeLa cells, HepG2 cells) and negative controls (RPL29 knockout cells if available) can help validate experimental results.

How can researchers optimize immunohistochemistry protocols for RPL29 detection in different tissue types?

For optimal RPL29 immunohistochemistry:

• Antigen retrieval is crucial: Use TE buffer pH 9.0 or citrate buffer pH 6.0

• Antibody dilutions should be optimized for each tissue type, typically starting with 1:50-1:500

• For mouse brain and human cancer tissues, which have been validated for positive staining , begin with established protocols

• For other tissue types, perform dilution series and antigen retrieval method comparisons

• Include positive control tissues (mouse brain, human breast cancer, human liver cancer)

• For dual staining with cell-type specific markers, optimize each antibody individually before combining

• Consider tissue-specific autofluorescence and take appropriate countermeasures (such as Sudan Black B treatment for high-lipid tissues)

These optimizations can help ensure specific and reproducible RPL29 detection across different tissue types.